Control of Autophagic Cell Death by Caspase-10 in Multiple Myeloma

Get Permission

Multiple myeloma subtypes are driven by a variety of genetic abnormalities. Given the genetic diversity of the disease, identification of oncogenic mechanisms common to all subtypes is highly desirable. In a study reported in Cancer Cell, Lamy and colleagues found that that all multiple myeloma lines require caspase-10 for survival irrespective of their genetic abnormalities. This effect of caspase-10, which was unexpectedly discovered during loss-of-function RNA interference screening to identify therapeutic targets in multiple myeloma, occurs through inhibition of autophagic cell death.

The investigators found that the transcription factor IRF4, a master regulator of the plasma cell phenotype found at higher levels in multiple myeloma than in normal plasma cells, induces both caspase-10 and its associated protein cFLIPL in multiple myeloma. This results in a caspase-10/cFLIPL protease that blocks an autophagy-dependent cell death pathway.

In particular, caspase-10 was found to promote survival by cleaving BCLAF1 (BCL2-interacting protein), an inducer of autophagic death that acts by displacing beclin-1 from BCL2. As a result of an as-yet undefined mechanism, multiple myeloma cells preferentially express cFLIPL, which promotes caspase-10 activity, and not the inhibitory cFLIPS isoform.

In the context of this finding, the investigators stated, “Caspase-10 modulates this autophagic response, preventing it from inducing cell death. Therapies targeting caspase-10 would exploit this regulatory pathway and could have broad efficacy across myeloma subtypes.” ■

Lamy L, et al: Cancer Cell 23:435-449, 2013.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.